Top

Clinical and Translational Oncology

Published in:

01-10-2020 | Radiotherapy | Research Article

Multifunctional nanocomposites MGO/FU-MI inhibit the proliferation of tumor cells and enhance the effect of chemoradiotherapy in vivo and in vitro

Authors: X. Peng, C. Yang, X. Kong, Y. Xiang, W. Dai, H. Quan

Published in: Clinical and Translational Oncology | Issue 10/2020

Abstract

Purpose

The limitation of surgery, radiotherapy and chemotherapy in the treatment of cancer and the rise of the application of nanomaterials in the field of biomedicine have promoted the application of various nanomaterials in the combination of radiotherapy and chemotherapy in the treatment of cancer. To improve the efficiency of cancer treatment, the multifunctional nanocomposites MGO/FU-MI (MGO/FU-MI NCs) were used for combination chemotherapy and radiotherapy to verify its effectiveness in treating tumors.

Methods

The proliferation activity of MGO/FU-MI NCs on MC-38 and B16 cells was detected by CCK-8, and the level of apoptosis and reactive oxygen species were detected by flow cytometry. To verify its efficacy in the combination of chemoradiotherapy, different treatment regimens were developed for several groups of tumor-bearing mice.

Results

The MGO/FU-MI NCs can induce apoptosis, stimulate ROS production, and inhibit cell proliferation. In vivo experiments, when MGO/FU-MI NCs are used alone for chemotherapy, have a certain therapeutic effect on mouse tumors. When MGO/FU-MI NCs are combined with radiation, the tumor volume can be significantly reduced and the survival time of mice is significantly prolonged.

Conclusion

The MGO/FU-MI NCs are very effective in the treatment of tumors when combined with radiotherapy and chemotherapy, and have the potential to be a combination of radiotherapy and chemotherapy.

Bouras A, Kaluzova M, Hadjipanayis CG. Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles. J Neuro-Oncol. 2015;124(1):13–22. https://doi.org/10.1007/s11060-015-1807-0.CrossRef

Xie X, Zhang X, Chen J, Tang X, Wang M, Zhang L, et al. Fe₃O₄-solamargine induces apoptosis and inhibits metastasis of pancreatic cancer cells. Int J Oncol. 2019;54(3):905–15. https://doi.org/10.3892/ijo.2018.4637.CrossRefPubMed

Schiff E, Ben-Arye E. Complementary therapies for side effects of chemotherapy and radiotherapy in the upper gastrointestinal system. Eur J Integr Med. 2011;3(1):11–6. https://doi.org/10.1016/j.eujim.2011.02.006.CrossRef

Song G, Cheng L, Chao Y, Yang K, Liu Z. Emerging nanotechnology and advanced materials for cancer radiation therapy. Adv Mater. 2017. https://doi.org/10.1002/adma.201700996.CrossRefPubMedPubMedCentral

Bao Z, He M, Quan H, Jiang D, Zheng Y, Qin W, et al. FePt nanoparticles: a novel nanoprobe for enhanced HeLa cells sensitivity to chemoradiotherapy. Rsc Adv. 2016;6(41):35124–34. https://doi.org/10.1039/c6ra03990a.CrossRef

Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol. 2008;88(2):258–68. https://doi.org/10.1016/j.radonc.2008.04.005.CrossRefPubMed

Chan N, Milosevic M, Bristow RG. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol. 2007;3(3):329–41. https://doi.org/10.2217/14796694.3.3.329.CrossRefPubMed

Sun Y, Miao H, Ma S, Zhang L, You C, Tang F, et al. FePt-Cys nanoparticles induce ROS-dependent cell toxicity, and enhance chemo-radiation sensitivity of NSCLC cells in vivo and in vitro. Cancer Lett. 2018;418:27–40. https://doi.org/10.1016/j.canlet.2018.01.024.CrossRefPubMed

Ma S, Miao H, Luo Y, Sun Y, Tian X, Wang F, et al. FePt/GO nanosheets suppress proliferation, enhance radiosensitization and induce autophagy of human non-small cell lung cancer cells. Int J Biol Sci. 2019;15(5):999–1009. https://doi.org/10.7150/ijbs.29805.CrossRefPubMedPubMedCentral

10.

Yue L, Wang J, Dai Z, Hu Z, Chen X, Qi Y, et al. pH-responsive, self-sacrificial nanotheranostic agent for potential in vivo and in vitro dual modal MRI/CT imaging, real-time, and in situ monitoring of cancer therapy. Bioconjug Chem. 2017;28(2):400–9. https://doi.org/10.1021/acs.bioconjchem.6b00562.CrossRefPubMed

11.

Fuchigami T, Kawamura R, Kitamoto Y, Nakagawa M, Namiki Y. A magnetically guided anti-cancer drug delivery system using porous FePt capsules. Biomaterials. 2012;33(5):1682–7. https://doi.org/10.1016/j.biomaterials.2011.11.016.CrossRefPubMed

12.

Xu C, Yuan Z, Kohler N, Kim J, Chung MA, Sun S. FePt nanoparticles as an Fe reservoir for controlled Fe release and tumor inhibition. J Am Chem Soc. 2009;131(42):15346–51. https://doi.org/10.1021/ja905938a.CrossRefPubMedPubMedCentral

13.

Zheng Y, Tang Y, Bao Z, Wang H, Ren F, Guo M, et al. FePt nanoparticles as a potential X-ray activated chemotherapy agent for HeLa cells. Int J Nanomedicine. 2015;10:6435–44. https://doi.org/10.2147/IJN.S88458.CrossRefPubMedPubMedCentral

14.

Solanki A, Chueng ST, Yin PT, Kappera R, Chhowalla M, Lee KB. Axonal alignment and enhanced neuronal differentiation of neural stem cells on graphene-nanoparticle hybrid structures. Adv Mater. 2013;25(38):5477–82. https://doi.org/10.1002/adma.201302219.CrossRefPubMedPubMedCentral

15.

Tanzer K, Feketeova L, Puschnigg B, Scheier P, Illenberger E, Denifl S. Reactions in nitroimidazole and methylnitroimidazole triggered by low-energy (0–8 eV) electrons. J Phys Chem A. 2015;119(25):6668–75. https://doi.org/10.1021/acs.jpca.5b02721.CrossRefPubMed

16.

Feketeova L, Postler J, Zavras A, Scheier P, Denifl S, O'Hair RA. Decomposition of nitroimidazole ions: experiment and theory. Phys Chem Chem Phys. 2015;17(19):12598–607. https://doi.org/10.1039/c5cp01014d.CrossRefPubMed

17.

Liu H, Xie Y, Zhang Y, Cai Y, Li B, Mao H, et al. Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma. Biomaterials. 2017;121:130–43. https://doi.org/10.1016/j.biomaterials.2017.01.001.CrossRefPubMed

18.

Urtasun R, Band P, Chapman JD, Feldstein ML, Mielke B, Fryer C. Radiation and high-dose metronidazole in supratentorial glioblastomas. New Engl J Med. 1976;294(25):1364–7. https://doi.org/10.1056/NEJM197606172942503.CrossRefPubMed

19.

Farquharson S, Gift A, Shende C, Inscore F, Ordway B, Farquharson C, et al. Surface-enhanced Raman spectral measurements of 5-fluorouracil in saliva. Molecules. 2008;13(10):2608–27. https://doi.org/10.3390/molecules13102608.CrossRefPubMedPubMedCentral

20.

Arias JL. Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules. 2008;13(10):2340–69. https://doi.org/10.3390/molecules13102340.CrossRefPubMedPubMedCentral

21.

Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8. https://doi.org/10.1038/nrc1074.CrossRefPubMed

22.

Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001;1(1):65–70.CrossRefPubMed

23.

Yang C, Peng S, Sun Y, Miao H, Lyu M, Ma S, et al. Development of a hypoxic nanocomposite containing high-Z element as 5-fluorouracil carrier activated self-amplified chemoradiotherapy co-enhancement. R Soc Open Sci. 2019;6(6):181790. https://doi.org/10.1098/rsos.181790.CrossRefPubMedPubMedCentral

24.

Takahashi J, Misawa M. Characterization of reactive oxygen species generated by protoporphyrin IX under X-ray irradiation. Radiat Phys Chem. 2009;78(11):889–98. https://doi.org/10.1016/j.radphyschem.2009.06.036.CrossRef

25.

Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6(7):535–45. https://doi.org/10.1038/nrc1894.CrossRefPubMedPubMedCentral

26.

Bonvalot S, Rutkowski PL, Thariat J, Carrere S, Ducassou A, Sunyach MP, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. Lancet Oncol. 2019;20(8):1148–59. https://doi.org/10.1016/S1470-2045(19)30326-2.CrossRefPubMed

27.

Yu Y, Duan J, Yu Y, Li Y, Liu X, Zhou X, et al. Silica nanoparticles induce autophagy and autophagic cell death in HepG2 cells triggered by reactive oxygen species. J Hazard Mater. 2014;270:176–86. https://doi.org/10.1016/j.jhazmat.2014.01.028.CrossRefPubMed

28.

Akhtar MJ, Ahamed M, Kumar S, Khan MAM, Ahmad J, Alrokayan SA. Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species. Int J Nanomed. 2012;7:845–57. https://doi.org/10.2147/IJN.S29129.CrossRef

Title: Multifunctional nanocomposites MGO/FU-MI inhibit the proliferation of tumor cells and enhance the effect of chemoradiotherapy in vivo and in vitro
Authors: X. Peng
C. Yang
X. Kong
Y. Xiang
W. Dai
H. Quan
Publication date: 01-10-2020
Publisher: Springer International Publishing
Keywords: Radiotherapy
Cytostatic Therapy
Published in: Clinical and Translational Oncology / Issue 10/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02331-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2020

PRDX2 plays an oncogenic role in esophageal squamous cell carcinoma via Wnt/β-catenin and AKT pathways

Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

The risk of malignancies in patients receiving hematopoietic stem cell transplantation: a systematic review and meta-analysis

Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice

RUNX1-activated upregulation of lncRNA RNCR3 promotes cell proliferation, invasion, and suppresses apoptosis in colorectal cancer via miR-1301-3p/AKT1 axis in vitro and in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer